If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...

After Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...

Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...

A CML diagnosis, often striking young Indian adults, is now more manageable. This guide emphasizes empowering patients by ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer. It starts in blood-forming cells within the bone marrow, creating leukemia cells. These cells transfer ...

Patient adherence to tyrosine kinase inhibitors (TKIs) ranges widely—from 19% to 100%—according to several studies. Most participants in the current study believed in the efficacy of their medication, ...

Genetic testing for chronic myeloid leukemia (CML) can tell doctors if someone has leukemia, what type they may have, and whether treatment is working. The tests look for atypical changes in certain ...

CML Microsystems ( ($GB:CML) ) has issued an announcement. CML Microsystems has announced the issuance of new ordinary shares to Non-Executive ...

A Charlotte-based library services company will close its doors next year. Baker & Taylor will shutter its headquarters off ...